A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
VSR; Palivizumab; Inmunoglobulina contra el virus sincicial respiratorio
Una manera simple de ayudar a prevenir el VSR es lavándose las manos con frecuencia, especialmente antes de tocar al bebé. Es importante asegurarse de que otras personas, especialmente los cuidadores, tomen precauciones para evitar contagiar al bebé con este virus.
Las siguientes medidas simples pueden ayudar a proteger al bebé de la enfermedad:
Los padres que tienen bebés pequeños en alto riesgo deben evitar las multitudes durante los brotes del VSR. En los noticieros y periódicos locales frecuentemente se informa sobre brotes que van de moderados a graves con el fin de brindar a los padres una oportunidad de evitar la exposición.
El medicamento Synagis (palivizumab) está aprobado para prevenir la enfermedad por el VSR en niños menores de dos años que estén en alto riesgo de contraerla en forma grave. Pregúntele al médico si el niño debe recibir este medicamento.
Committee on Infectious Diseases. Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694-1701.
Respiratory Syncytial Virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2009:chap158.
Cincinnati Children's Hospital Medical Center. Evidence based clinical practice guideline for medical management of bronchiolitis in infants less than 1 year of age presenting with a first time episode. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2006 May. 13 p.
Mcintosh K. Respiratory syncytial virus. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson Textbook of Pediatrics. 18th ed. Philadelphia, Pa: Saunders Elsevier;2007:chap 257.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885